Skip to main content

Advertisement

SpringerLink
Log in

The Approach to Antibodies After Heart Transplantation

  • Thoracic Transplantation (J Kobashigawa, Section Editor)
  • Published:
Current Transplantation Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This review summarizes recent data about antibodies after cardiac transplantation, what testing modalities are available and how frequently to employ them, and when treatment is necessary.

Recent Findings

Technologies available for antibody detection have progressed over the past couple decades. New and preformed antibodies are associated with worse outcomes in transplant recipients.

Summary

The frequency of screening for post-transplant antibodies and for antibody-mediated rejection (AMR) should be based on risk stratification. The presence of antibodies alone post transplant does not constitute a diagnosis of AMR. Treatment of post-transplant antibodies and AMR should be made in conjunction with consideration of AMR grade and graft dysfunction. Future directions will involve improved detection methods and further understanding of non-HLA antibodies and de novo antibodies in the post-transplant population. Additionally, aggressive efforts are currently underway to provide more therapeutic options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Terasaki PI. Humoral theory of transplantation. Am J Transplant. 2003;3(6):665–73.

    Article  PubMed  Google Scholar 

  2. Brasile L, Zerbe T, Rabin B, Clarke J, Abrams A, Cerilli J. Identification of the antibody to vascular endothelial cells in patients undergoing cardiac transplantation. Transplantation. 1985;40(6):672–5.

    Article  CAS  PubMed  Google Scholar 

  3. Massad MG, Cook DJ, Schmitt SK, Smedira NG, McCarthy JF, Vargo RL, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64(4):1120–5.

    Article  CAS  PubMed  Google Scholar 

  4. Fuller TC, Fuller A. The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder. Transplantation. 1999;68(2):173–82.

    Article  CAS  PubMed  Google Scholar 

  5. Mehra MR, Uber PA, Uber WE, Scott RL, Park MH. Allosensitization in heart transplantation: implications and management strategies. Curr Opin Cardiol. 2003;18(2):153–8.

    Article  PubMed  Google Scholar 

  6. Möller E, Söderberg-Nauclér C, Sumitran-Karuppan S. Role of alloimmunity in clinical transplantation. Rev Immunogenet. 1999;1(3):309–22.

    PubMed  Google Scholar 

  7. Arnaoutakis GJ, George TJ, Kilic A, Weiss ES, Russell SD, Conte JV, et al. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. J Thorac Cardiovasc Surg. 2011;142(5):1236–45.

  8. Castleberry C, Zafar F, Thomas T, Khan MS, Bryant R, Chin C, et al. Allosensitization does not alter post-transplant outcomes in pediatric patients bridged to transplant with a ventricular assist device. Pediatr Transplant. 2016;20(4):559–64.

    Article  PubMed  Google Scholar 

  9. Alba AC, Tinckam K, Foroutan F, Nelson LM, Gustafsson F, Sander K, et al. Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes. J Heart Lung Transplant. 2015;34(5):685–92.

    Article  PubMed  Google Scholar 

  10. Shankar N, Daly R, Geske J, Kushwaha SK, Timmons M, Joyce L, et al. LVAD implant as a bridge to heart transplantation is associated with allosensitization as measured by single antigen bead assay. Transplantation. 2013;96(3):324–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kidambi S, Mohamedali B, Bhat G. Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices. Clin Transpl. 2015;29(6):499–505.

    Article  CAS  Google Scholar 

  12. Ko BS, Drakos S, Kfoury AG, Hurst D, Stoddard GJ, Willis CA, et al. Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant. J Heart Lung Transplant. 2016;35(8):1024–30.

    Article  PubMed  Google Scholar 

  13. Ho EK, Vlad G, Vasilescu ER, de la Torre L, Colovai AI, Burke E, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol. 2011;72(1):5–10.

    Article  CAS  PubMed  Google Scholar 

  14. Smith JD, Banner NR, Hamour IM, Ozawa M, Goh A, Robinson D, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11(2):312–9.

    Article  CAS  PubMed  Google Scholar 

  15. Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, Dunlap S, Montpetit M, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005;80(8):1019–25.

    Article  PubMed  Google Scholar 

  16. Kaczmarek I, Deutsch MA, Kauke T, Beiras-Fernandez A, Schmoeckel M, Vicol C, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant. 2008;6(3):229–35.

    PubMed  Google Scholar 

  17. •• Colvin MM, Cook JL, Chang P, Francis G, Hsu DT, Kiernan MS, et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015;131(18):1608–39. This document encapsulates the history of our undestanding of AMR and makes recommendations on diagnosis, surveillance, and management

    Article  PubMed  Google Scholar 

  18. Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95(9):1113–9.

    Article  CAS  PubMed  Google Scholar 

  19. Irving CA, Carter V, Gennery AR, Parry G, Griselli M, Hasan A, et al. Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation. J Heart Lung Transplant. 2015;34(10):1310–7.

    Article  PubMed  Google Scholar 

  20. DeVos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int. 2012;82(5):598–604.

    Article  CAS  PubMed  Google Scholar 

  21. •• Al-Mohaissen MA, Virani SA. Allosensitization in heart transplantation: an overview. Can J Cardiol. 2014;30(2):161–72. This is a contemporary review of risk factors, testing, and management of allosensitization

    Article  PubMed  Google Scholar 

  22. Alvarez-Márquez A, Aguilera I, Blanco RM, Pascual D, Encarnación-Carrizosa M, Alvarez-López MR, et al. Positive association of anticytoskeletal endothelial cell antibodies and cardiac allograft rejection. Hum Immunol. 2008;69(3):143–8.

    Article  PubMed  Google Scholar 

  23. Barz D, Friedrich S, Schuller A, Rummler S. Antibodies against AT1-receptor in transplantation (diagnostics, treatment, clinical relevance). Atheroscler Suppl. 2015;18:112–8.

    Article  PubMed  Google Scholar 

  24. • Reinsmoen NL, Lai CH, Mirocha J, Cao K, Ong G, Naim M, et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation. 2014;97(5):595–601. This investigation demonstrates the negative impact of both HLA and non-HLA de novo antibodies on cardiac graft outcomes

    Article  CAS  PubMed  Google Scholar 

  25. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710–20.

    Article  PubMed  Google Scholar 

  26. Reed EF, Demetris AJ, Hammond E, Itescu S, Kobashigawa JA, Reinsmoen NL, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25(2):153–9.

    Article  PubMed  Google Scholar 

  27. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(3):252–69.

    Article  PubMed  Google Scholar 

  28. •• Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32(12):1147–62. This documented provided updates to the 2010 ISHLT consensus document with the reducing vairation in the diagnosis of AMR in order to improve algorithms for therapy

    Article  PubMed  Google Scholar 

  29. Berry GJ, Angelini A, Burke MM, Bruneval P, Fishbein MC, Hammond E, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J Heart Lung Transplant. 2011;30(6):601–11.

    Article  PubMed  Google Scholar 

  30. •• Bruneval P, Angelini A, Miller D, Potena L, Loupy A, Zeevi A, et al. The XIIIth Banff Conference on Allograft Pathology: the Banff 2015 Heart Meeting Report: improving antibody-mediated rejection diagnostics: strengths, unmet needs, and future directions. Am J Transplant. 2017;17(1):42–53. In addition to analyzing the strengths and weakness of the current rejection grading system, detection methods, and management, this documenton suggests standardization of our approach to CAV

    Article  CAS  PubMed  Google Scholar 

  31. Zachary AA, Ratner LE, Graziani JA, Lucas DP, Delaney NL, Leffell MS. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. Hum Immunol. 2001;62(3):236–46.

    Article  CAS  PubMed  Google Scholar 

  32. Pei R, Lee J, Chen T, Rojo S, Terasaki PI. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol. 1999;60(12):1293–302.

    Article  CAS  PubMed  Google Scholar 

  33. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation. 2003;75(1):43–9.

    Article  CAS  PubMed  Google Scholar 

  34. •• Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95(1):19–47. In the face of increased sensitivity and specificity availabe with SPIs, this document defined low-, intermediate-, and high-risk patients based on allosensitization risk to warrant frequency of antibody testing

    Article  CAS  PubMed  Google Scholar 

  35. • Ellis TM. Interpretation of HLA single antigen bead assays. Transplant Rev (Orlando). 2013;27(4):108–11. This is a review of our current understanding of the benefits and limitations intrinsic to SAB assays for the detection and quantitation of HLA antibodies

    Article  Google Scholar 

  36. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies—a new tool for prediction of graft failure after heart transplantation. Am J Transplant. 2007;7(12):2809–15.

    Article  CAS  PubMed  Google Scholar 

  37. Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011;30(2):158–63.

    Article  PubMed  Google Scholar 

  38. Llorente S, Boix F, Eguia J, López M, Bosch A, Martinez H, et al. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG. Transplant Proc. 2012;44(9):2535–7.

  39. Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013;32(1):98–105.

    Article  PubMed  Google Scholar 

  40. Kaufman BD, Shaddy RE. Immunologic considerations in heart transplantation for congenital heart disease. Curr Cardiol Rev. 2011;7(2):67–71.

  41. • Guichard-Romero A, Marino-Vazquez LA, Castelán N, López M, González-Tableros N, Arvizu A, et al. Impact of pretransplant exposure to allosensitization factors generating HLA antibodies in the Luminex era. Transpl Immunol. 2016;38:33–9. This study used Luminex measurement of PRA to assess attributatable risk of sensitizing factors

    Article  CAS  PubMed  Google Scholar 

  42. Leech SH, Lopez-Cepero M, LeFor WM, DiChiara L, Weston M, Furukawa S, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transpl. 2006;20(4):476–84.

    Article  CAS  Google Scholar 

  43. Kobashigawa JA, Patel JK, Kittleson MM, Kawano MA, Kiyosaki KK, Davis SN, et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transpl. 2011;25(1):E61–7.

    Article  Google Scholar 

  44. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30(12):1320–6.

    Article  PubMed  Google Scholar 

  45. Bućin D, Gustafsson R, Ekmehag B, Kornhall B, Algotsson L, Lund U, et al. Desensitization and heart transplantation of a patient with high levels of donor-reactive anti-human leukocyte antigen antibodies. Transplantation. 2010;90(11):1220–5.

    Article  PubMed  Google Scholar 

  46. Daly KP, Chandler SF, Almond CS, Singh TP, Mah H, Milford E, et al. Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients. Pediatr Transplant. 2013;17(7):661–9.

    PubMed  Google Scholar 

  47. Jackups R, Canter C, Sweet SC, Mohanakumar T, Morris GP. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection. J Clin Apher. 2013;28(4):301–8.

    Article  PubMed  Google Scholar 

  48. Larson DF, Elkund DK, Arabia F, Copeland JG. Plasmapheresis during cardiopulmonary bypass: a proposed treatment for presensitized cardiac transplantation patients. J Extra Corpor Technol. 1999;31(4):177–83.

    CAS  PubMed  Google Scholar 

  49. Lick SD, Beckles DL, Piovesana G, Vaidya S, Indrikovs A, Barbagelata NA, et al. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. Ann Thorac Surg. 2011;92(4):1428–34.

    Article  PubMed  Google Scholar 

  50. Holt DB, Lublin DM, Phelan DL, Boslaugh SE, Gandhi SK, Huddleston CB, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant. 2007;26(9):876–82.

    Article  PubMed  Google Scholar 

  51. Pollock-BarZiv SM, den Hollander N, Ngan BY, Kantor P, McCrindle B, West LJ, et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation. 2007;116(11 Suppl):I172–8.

    PubMed  Google Scholar 

  52. Schumacher KR, Ramon DS, Kamoun M, Caruthers R, Gajarski RJ. HLA desensitization in pediatric heart transplant candidates: efficacy of rituximab and IVIg. J Heart Lung Transplant. 2012;31(9):1041–2.

    Article  PubMed  Google Scholar 

  53. John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation. 1999;100(19 Suppl):II229–35.

    CAS  PubMed  Google Scholar 

  54. Pisani BA, Mullen GM, Malinowska K, Lawless CE, Mendez J, Silver MA, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18(7):701–6.

    Article  CAS  PubMed  Google Scholar 

  55. Richmond ME, Hsu DT, Mosca RS, Chen J, Quaegebeur JM, Addonizio LJ, et al. Outcomes in pediatric cardiac transplantation with a positive HLA cross-match. Pediatr Transplant. 2012;16(1):29–35.

    Article  PubMed  Google Scholar 

  56. Weeks P, Sieg A, Ling M, Bai Y, Nathan S, Rajapreyar I. Carfilzomib-rituximab desensitization in sensitized heart transplant candidates: a single center expereince. J Heart Lung Transplant. 2016;35(4):S76.

  57. Bonaros N, Dunkler D, Kocher A, Imhof M, Grimm M, Zuckermann A, et al. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation. J Heart Lung Transplant. 2006;25(9):1154–63.

    Article  PubMed  Google Scholar 

  58. Carrier M, Leblanc MH, Perrault LP, White M, Doyle D, Beaudoin D, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant. 2007;26(3):258–63.

    Article  PubMed  Google Scholar 

  59. De Santo LS, Della Corte A, Romano G, Amarelli C, Onorati F, Torella M, et al. Midterm results of a prospective randomized comparison of two different rabbit-antithymocyte globulin induction therapies after heart transplantation. Transplant Proc. 2004;36(3):631–7.

    Article  PubMed  Google Scholar 

  60. Emin A, Rogers CA, Thekkudan J, Bonser RS, Banner NR, Steering Group UKCTA. Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study. J Heart Lung Transplant. 2011;30(7):770–7.

    Article  PubMed  Google Scholar 

  61. Faggian G, Forni A, Milano AD, Chiominto B, Walpoth BH, Scarabelli T, et al. Antithymocyte globulin induction therapy in heart transplantation: prospective randomized study of high vs standard dosage. Transplant Proc. 2010;42(9):3679–87.

    Article  CAS  PubMed  Google Scholar 

  62. Koch A, Daniel V, Dengler TJ, Schnabel PA, Hagl S, Sack FU. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat). J Heart Lung Transplant. 2005;24(6):708–13.

    Article  PubMed  Google Scholar 

  63. Krogsgaard K, Boesgaard S, Aldershvile J, Arendrup H, Mortensen SA, Petterson G. Cytomegalovirus infection rate among heart transplant patients in relation to the potency of antithymocyte immunoglobulin induction therapy. Copenhagen Heart Transplant Group. Transplant Proc. 1994;26(3):1718.

    CAS  PubMed  Google Scholar 

  64. Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant. 2007;26(7):693–9.

    Article  PubMed  Google Scholar 

  65. Ladowski JS, Dillon T, Schatzlein MH, Peterson AC, Deschner WP, Beatty L, et al. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol. J Cardiovasc Surg. 1993;34(2):135–40.

    CAS  Google Scholar 

  66. Yamani MH, Taylor DO, Czerr J, Haire C, Kring R, Zhou L, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transpl. 2008;22(1):76–81.

    Google Scholar 

  67. Zhang R, Haverich A, Strüber M, Simon A, Bara C. Delayed onset of cardiac allograft vasculopathy by induction therapy using anti-thymocyte globulin. J Heart Lung Transplant. 2008;27(6):603–9.

    Article  CAS  PubMed  Google Scholar 

  68. Beniaminovitz A, Itescu S, Lietz K, Donovan M, Burke EM, Groff BD, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 2000;342(9):613–9.

    Article  CAS  PubMed  Google Scholar 

  69. Delgado DH, Miriuka SG, Cusimano RJ, Feindel C, Rao V, Ross HJ. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant. 2005;24(2):166–9.

    Article  PubMed  Google Scholar 

  70. Rosenberg PB, Vriesendorp AE, Drazner MH, Dries DL, Kaiser PA, Hynan LS, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant. 2005;24(9):1327–31.

    Article  PubMed  Google Scholar 

  71. Segovia J, Rodríguez-Lambert JL, Crespo-Leiro MG, Almenar L, Roig E, Gómez-Sánchez MA, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation. 2006;81(11):1542–8.

    Article  CAS  PubMed  Google Scholar 

  72. Itescu S, Burke E, Lietz K, John R, Mancini D, Michler R, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation. 2002;105(10):1214–9.

    Article  CAS  PubMed  Google Scholar 

  73. Lick SD, Vaidya S, Kollar AC, Boor PJ, Vertrees RA. Peri-operative alemtuzumab (Campath-1H) and plasmapheresis for high-PRA positive lymphocyte crossmatch heart transplant: a strategy to shorten left ventricular assist device support. J Heart Lung Transplant. 2008;27(9):1036–9.

    Article  PubMed  Google Scholar 

  74. Patel L, Dilibero D, Kittleson M, Sana S, Liou F, Chang D, et al. Terminal complement inhibition for highly sensitized patients undergoing heart transplant—doable? J Heart Lung Transplant. 2015;34(4):S31.

  75. • Chih S, Patel J. Desensitization strategies in adult heart transplantation—will persistence pay off. J Heart Lung Transplant. 2016;35(8):962–72. This review provides an overview of current desensitization strategies, limitations, and future directions

    Article  PubMed  Google Scholar 

  76. Marques MB, Schwartz J. Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apher. 2011;26(3):146–51.

    Article  PubMed  Google Scholar 

  77. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914–56.

    Article  PubMed  Google Scholar 

  78. Chih S, Tinckam KJ, Ross HJ. A survey of current practice for antibody-mediated rejection in heart transplantation. Am J Transplant. 2013;13(4):1069–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7075, USA

    Olivia N. Gilbert & Patricia P. Chang

Authors
  1. Olivia N. Gilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia P. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patricia P. Chang.

Ethics declarations

Conflict of Interest

Olivia Gilbert and Patricia Chang declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Thoracic Transplantation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gilbert, O.N., Chang, P.P. The Approach to Antibodies After Heart Transplantation. Curr Transpl Rep 4, 243–251 (2017). https://doi.org/10.1007/s40472-017-0162-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40472-017-0162-9

Keywords

Search

Navigation